Literature DB >> 26924152

Treatment of hypothyroidism: all that glitters is gold?

Anna Maria Formenti1, Gherardo Mazziotti2, Raffaele Giubbini3, Andrea Giustina4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 26924152     DOI： 10.1007/s12020-016-0882-0

Source DB:  PubMed          Journal:  Endocrine        ISSN： 1355-008X            Impact factor:   3.633


× No keyword cloud information.
  27 in total

Review 1.  Clinical review 115: effect of thyroxine therapy on serum lipoproteins in patients with mild thyroid failure: a quantitative review of the literature.

Authors:  M D Danese; P W Ladenson; C L Meinert; N R Powe
Journal:  J Clin Endocrinol Metab       Date:  2000-09       Impact factor: 5.958

2.  Guidelines for the treatment of hypothyroidism: prepared by the american thyroid association task force on thyroid hormone replacement.

Authors:  Jacqueline Jonklaas; Antonio C Bianco; Andrew J Bauer; Kenneth D Burman; Anne R Cappola; Francesco S Celi; David S Cooper; Brian W Kim; Robin P Peeters; M Sara Rosenthal; Anna M Sawka
Journal:  Thyroid       Date:  2014-12       Impact factor: 6.568

3.  Thyroxine treatment: absorption, malabsorption, and novel therapeutic approaches.

Authors:  Marco Centanni
Journal:  Endocrine       Date:  2012-10-25       Impact factor: 3.633

Review 4.  New understanding and treatments for osteoporosis.

Authors:  G Mazziotti; J Bilezikian; E Canalis; D Cocchi; A Giustina
Journal:  Endocrine       Date:  2012-02       Impact factor: 3.633

5.  Oral L-thyroxine liquid versus tablet in patients with hypothyroidism without malabsorption: a prospective study.

Authors:  Poupak Fallahi; Silvia Martina Ferrari; Alessandro Antonelli
Journal:  Endocrine       Date:  2015-12-31       Impact factor: 3.633

6.  A novel formulation of L-thyroxine (L-T4) reduces the problem of L-T4 malabsorption by coffee observed with traditional tablet formulations.

Authors:  Roberto Vita; Giovanna Saraceno; Francesco Trimarchi; Salvatore Benvenga
Journal:  Endocrine       Date:  2012-08-30       Impact factor: 3.633

7.  Altered intestinal absorption of L-thyroxine caused by coffee.

Authors:  Salvatore Benvenga; Luigi Bartolone; Maria Angela Pappalardo; Antonia Russo; Daniela Lapa; Grazia Giorgianni; Giovanna Saraceno; Francesco Trimarchi
Journal:  Thyroid       Date:  2008-03       Impact factor: 6.568

8.  Pharmacokinetics and potential advantages of a new oral solution of levothyroxine vs. other available dosage forms.

Authors:  C S Yue; C Scarsi; M P Ducharme
Journal:  Arzneimittelforschung       Date:  2012-11-15

9.  Serum TSH values and risk of vertebral fractures in euthyroid post-menopausal women with low bone mineral density.

Authors:  Gherardo Mazziotti; Teresa Porcelli; Ilaria Patelli; Pier Paolo Vescovi; Andrea Giustina
Journal:  Bone       Date:  2009-11-03       Impact factor: 4.398

10.  Association between l-thyroxine treatment, GH deficiency, and radiological vertebral fractures in patients with adult-onset hypopituitarism.

Authors:  G Mazziotti; M Mormando; A Cristiano; A Bianchi; T Porcelli; A Giampietro; F Maffezzoni; V Serra; L De Marinis; A Giustina
Journal:  Eur J Endocrinol       Date:  2014-06       Impact factor: 6.664
View more
  12 in total

1.  Undertreated hypothyroidism due to calcium or iron supplementation corrected by oral liquid levothyroxine.

Authors:  Salvatore Benvenga; Flavia Di Bari; Roberto Vita
Journal:  Endocrine       Date:  2017-02-03       Impact factor: 3.633

2.  Intestinal absorption and buccal absorption of liquid levothyroxine.

Authors:  Salvatore Benvenga; Flavia Di Bari
Journal:  Endocrine       Date:  2017-03-07       Impact factor: 3.633

3.  Is levothyroxine requirement the same for tablet and soft gel formulations?

Authors:  Vincenzo Di Donna; Rosa Maria Paragliola; Chiara de Waure; Giampaolo Papi; Alfredo Pontecorvi; Salvatore Maria Corsello
Journal:  Endocrine       Date:  2017-05-02       Impact factor: 3.633

4.  Comparative study between the effects of replacement therapy with liquid and tablet formulations of levothyroxine on mood states, self-perceived psychological well-being and thyroid hormone profile in recently thyroidectomized patients.

Authors:  Celestino Pio Lombardi; Raffaella Bocale; Angelina Barini; Antonella Barini; Annamaria D'Amore; Mauro Boscherini; Rocco Bellantone
Journal:  Endocrine       Date:  2016-07-07       Impact factor: 3.633

5.  Oral mucositis induced by treatment with soft gel formulation of levothyroxine.

Authors:  Erika Messina; Francesco Ferraù; Salvatore Cannavò
Journal:  Endocrine       Date:  2017-05-05       Impact factor: 3.633

Review 6.  Liquid and softgel levothyroxine use in clinical practice: state of the art.

Authors:  Camilla Virili; Pierpaolo Trimboli; Francesco Romanelli; Marco Centanni
Journal:  Endocrine       Date:  2016-07-29       Impact factor: 3.633

7.  Treatment of refractory and severe hypothyroidism with sublingual levothyroxine in liquid formulation.

Authors:  Carmela Peirce; Serena Ippolito; Alejandra Lanas; Marcella Pesce; Gilda Pontieri; Debora Arpaia; Giovanni Sarnelli; Bernadette Biondi
Journal:  Endocrine       Date:  2017-07-13       Impact factor: 3.633

Review 8.  Liquid L-thyroxine versus tablet L-thyroxine in patients on L- thyroxine replacement or suppressive therapy: a meta-analysis.

Authors:  Irakoze Laurent; Siying Tang; Manirakiza Astère; Kan Ran Wang; Shuhua Deng; Ling Xiao; Qi Fu Li
Journal:  Endocrine       Date:  2018-03-23       Impact factor: 3.633

9.  Tablet and oral liquid L-thyroxine formulation in the treatment of naïve hypothyroid patients with Helicobacter pylori infection.

Authors:  Danilo Ribichini; Giulia Fiorini; Andrea Repaci; Valentina Castelli; Luigi Gatta; Dino Vaira; Renato Pasquali
Journal:  Endocrine       Date:  2016-11-15       Impact factor: 3.633

10.  Drug interactions in users of tablet vs. oral liquid levothyroxine formulations: a real-world evidence study in primary care.

Authors:  Valeria Guglielmi; Alfonso Bellia; Elisa Bianchini; Gerardo Medea; Iacopo Cricelli; Paolo Sbraccia; Davide Lauro; Claudio Cricelli; Francesco Lapi
Journal:  Endocrine       Date:  2017-09-14       Impact factor: 3.633
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.